共 50 条
- [21] Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (04): : 335 - 342Lee, Y. H.Bae, S. -C.
- [22] COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB 2 MG AND 4 MG IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 285 - 285Lee, Y. H.Seo, Y. H.Song, G. G.
- [23] Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (06) : 293 - 298Song, Gwan GyuLee, Young Ho
- [24] Relative efficacy and safety of tofacitinib for treating psoriasis: A Bayesian network meta-analysis of randomized controlled trials[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (04) : 308 - 314Song, Gwan GyuLee, Young Ho
- [25] Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (SUPPL 1): : 97 - 106Ho Lee, YoungGyu Song, Gwan
- [26] Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (SUPPL 1): : 107 - 114Lee, Young HoSong, Gwan Gyu
- [29] Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials[J]. Clinical Rheumatology, 2018, 37 : 1471 - 1479Sang-Cheol BaeYoung Ho Lee